An observational study in Arthroplasty, Replacement, Shoulder, Glenoid Cavity and Osteoarthritis of the Shoulder, sponsored by Materialise. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Materialise · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Osteoarthritis with a site in Belgium — 5 open to participants now, 13 under way, 1 of them phase 3. Osteoarthritis · Belgium.
Among the 53 studies in Osteoarthritis with a site in Belgium, this one is the 15th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2019, is one of 15 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 41st registered.
2,974 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →5 of the 53 studies in Osteoarthritis with a site in Belgium are open now. Recruiting first, the newest first:
Anesthesiology department Iris South Hospitals · Sites in Belgium
Ages 18–60
Eli Lilly and Company · Sites in Belgium, United States, Argentina and 10 more countries
Ages 18+
Ziekenhuis Oost-Limburg · Sites in Belgium, Netherlands
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+ · Healthy volunteers
Vrije Universiteit Brussel · Sites in Belgium
Ages 50+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 286 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 100 across 601 observational studies indexed under Osteoarthritis.
Median enrollment 105 across the 38 interventional studies, 154 across the 15 observational. Of the 38 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 53 have an industry lead sponsor. The 10 most frequent:
Materialise is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Materialise has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
| NCT02351414MicroPort Orthopedics Inc.Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts | 2027-06 |
| NCT07727551Anesthesiology department Iris South HospitalsPreoperative Genicular Radiofrequency and Functional Outcomes After Total Knee Arthroplasty | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Osteoarthritis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This post-market follow-up study investigates improvement in clinical and radiological outcome after reversed total shoulder arthroplasty with the patient-specific Glenius Glenoid Reconstruction system
The Glenius glenoid implant is a solution for patients who need a reversed glenoid reconstruction (primary or revision) because of a severely damaged glenoid associated with severe bone loss. In these cases, standard reconstruction of the glenoid is not possible because of the lack of body support of the glenoid rim or columns.
The Glenius implant is custom-made prothesis: during pre-operative planning, the implant is designed based on a detailed 3D CT analysis of the defect with special reference to bone quality and the anatomy of the bone deficient glenoid. Optimized screw fixation trajectories are defined for each individual patient, which accommodate screws that are positioned and angled towards the best bone stock available in the glenoid/coracoid/scapula with each specific patient. The surgeon provides feedback on the the design and orientation of the implant needed to achieve the optimal inclination of the head and the position \& offset of the joint's centre of rotation.
Because Glenius is a relatively new product and only for use in specific and complex cases of severy glenoid erosion, follow-up data on the clinical and radiological outcome are scarce. With this study we aim to collect long-term clinical and radiological follow-up data for patients treated with Glenius in a uniform, standardized way.
The study population consists of patients having primary or revision shoulder joint replacement with severe glenoid bone defects caused by:(1) Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis, (2) Inflammatory degenerative joint disease such as rheumatoid arthritis or (3) Congenital malformations, posttraumatic deformities or removal of components during revision surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with a Glenius Glenoid Reconstruction System
Device: reversed glenoid prothesis
All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
Also known as: Glenius Glenoid Reconstruction system
Change in baseline Constant-Murley Score after surgery
The Constant-Murley score is a clinical outcome scale composed of a number of individual parameters, defining the level of pain, the ability to carry out the normal daily activities of the patient, mobility and strength of the arm. The scores range from 0 (worst clinical outcome) to 100 (best clinical outcome).
Time frame: 6 weeks, 3 months, 1 year, 2 year, 5 years after surgery
Change in baseline Simple Shoulder Test (SST) after surgery
The SST is a function scale with 12 items, used to assess improvement in shoulder function after treatment interventions and to check the patient's ability to tolerate or perform 12 activities of daily living. The scores range from 0 (worst functional outcome) to 100 (best functional outcome).
Time frame: 6 weeks, 3 months, 1 year, 2 year, 5 years after surgery
Change in baseline Oxford Shoulder Score (OSS) after surgery
The OSS is a 12-item patient-reported outcome specifically designed and developed for assessing outcomes of shoulder surgery e.g. for assessing the impact on patients' quality of life of degenerative conditions such as arthritis and rotator cuff problems. The score ranges from 0 (no pain or functional impairement) to 60 (worst pain and functional impairement).
Time frame: 6 weeks, 3 months, 1 year, 2 year, 5 years after surgery
change in general health EQ5D score after surgery
EQ-5D is a standardized patient-reported outcome for measuring generic health status. The questionnaire has two components: a health state description measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. and a general evaluation of their overall health status using the visual analogue scale (EQ-VAS).
Time frame: 6 weeks, 3 months, 1 year, 2 year, 5 years after surgery
change in baseline pain score using Visual Analogue Scales (VAS) after surgery
The VAS pain score is a patient-reported evaluation of pain intensity on a Visual Analogue Scales (VAS) between 0 (no pain) and 100 (worst pain imaginable).
Time frame: 6 weeks, 3 months, 1 year, 2 year, 5 years after surgery
Translational deviation from planned implant position
translational deviation (in mm) of the implant position on post-operative shoulder CT scan when compared to the planned position on the pre-operative CT scan.
Time frame: 6 weeks after surgery
Rotational deviation from planned implant position
Rotational deviation (in degrees) of the implant position on post-operative shoulder CT scan when compared to the planned position on the pre-operative CT scan.
Time frame: 6 weeks after surgery
Translational deviation from initial implant position
translational deviation (in mm) on a shoulder CT scan 1 year after surgery, compared to the position on the post-operative CT scan.
Time frame: 1 year after surgery
Rotational deviation from initial implant position
Rotational deviation (in degrees) on a shoulder CT scan 1 year after surgery, compared to the position on the post-operative CT scan.
Time frame: 1 year after surgery
Scapular notching
scapular notching will be graded according to the Sirveaux classification system (2004) on a shoulder radiograph. The classification goes from 0 (no notching) to 4 (erosion over the inferior screw with extension under the baseplate)
Time frame: 6 weeks, 3 months, 1 year, 2 years, 5 years after surgery
Radiolucensies
Radiolucencies surrounding the glenoid component will be graded according to the system of Lazarus (Lazarus et al 2002) on a shoulder radiograph. The classification goes from 0 (no lucensies) to 5 (gross lucensies and radiographic loosening)
Time frame: 6 weeks, 3 months, 1 year, 2 years, 5 years after surgery
Heterotopic ossifications
periarticular heterotopic ossification (HO) will be scored according to a modified Brooker classification system of HO of the hip (Verhofste et al 2016) on a shoulder radiograph. The classification goes from 0 (no ossifications) to 3 (complete ankylosis of the shoulder)
Time frame: 6 weeks, 3 months, 1 year, 2 years, 5 years after surgery
rate of implant revision surgeries up to 5 years after surgery
Implant survival will be calculated by calculating the rate of implant revision surgeries up to 5 years after surgery.
Time frame: up to 5 years after surgery
Complication rate
the number and kind of (severe) adverse (device) events: device/shoulder related A(D)Es, SA(D)Es and device deficiencies that could have led to an SAE will be collected.
Time frame: up to 5 year after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2019 (actual). Primary completion is estimated for Mar 2030, 128 months after the start.
Of 82 industry-sponsored observational studies under Osteoarthritis, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 184. This study's planned 128 months is above that.
Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Oct 2024 → Mar 2030 and completion Dec 2028 → Mar 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Materialise